Acromegaly Clinical Trial Landscape
Data updated: May 20, 2026
48 clinical trials tracked since 2008
Acromegaly is being studied across 48 clinical trials registered since 2008, with 6 programs currently active. The competitive pipeline includes 3 active Phase 3 trials, 2 active Phase 2 trials, and 1 active Phase 1 trials. Top industry sponsors include Crinetics Pharmaceuticals Inc., Debiopharm International SA, AstraZeneca.
6 active
/
48 total (since 2008)
1
Phase 1 Active
9 total
2
Phase 2 Active
18 total
3
Phase 3 Active
16 total
0
Phase 4 Active
6 total
Top Industry Sponsors
Sorted by active Active Done Failed
Crinetics Pharmaceuticals Inc. 3 2 0
Debiopharm International SA 1 0 1
AstraZeneca 1 0 0
Marea Therapeutics 1 0 0
Ipsen 0 4 3
+ 3 more sponsors — see full table below
Featured Phase 3 Trials
NCT06930625 RECRUITING
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA n=119
NCT05192382 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Crinetics Pharmaceuticals Inc. n=111
NCT04837040 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals Inc. n=58
NCT04125836 COMPLETED
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=135
NCT04076462 COMPLETED
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=72
+ 11 more Phase 3 trials — see full database below
Acromegaly — Trials Started by Year (last 10 years)
2016 2
2017 2
2018 2
2019 7
2020 1
2021 3
2022 1
2023 1
2024 1
2025 3
2026 0
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Crinetics Pharmaceuticals Inc. 5
Debiopharm International SA 2
AstraZeneca 1
Marea Therapeutics 1
Ipsen 7
Novartis 5
Camurus AB 3
Ionis Pharmaceuticals, Inc. 3
Chiasma, Inc. 2
Ono Pharmaceutical Co., Ltd. 2
Active Trials by Phase
Phase 1 1
Phase 2 2
Phase 3 3
Enrollment Size Distribution
1-50 25
51-200 18
201-500 4
501-1k 0
1k+ 0
All Industry Sponsors
Sorted by active Active Done Failed
Crinetics Pharmaceuticals Inc. 3 2 0
Debiopharm International SA 1 0 1
AstraZeneca 1 0 0
Marea Therapeutics 1 0 0
Ipsen 0 4 3
Novartis 0 5 0
Camurus AB 0 3 0
Ionis Pharmaceuticals, Inc. 0 3 0
NCT06930625 RECRUITING
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA n=119
NCT05192382 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Crinetics Pharmaceuticals Inc. n=111
NCT04837040 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals Inc. n=58
NCT04125836 COMPLETED
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=135
NCT04076462 COMPLETED
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=72
NCT00690898 COMPLETED
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Ipsen n=108
NCT02685709 COMPLETED
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Chiasma, Inc. n=146
NCT02354508 COMPLETED
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis Pharmaceuticals n=123
NCT02493517 COMPLETED
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Ipsen n=128
NCT01137682 COMPLETED
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Novartis Pharmaceuticals n=198
NCT01412424 COMPLETED
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Chiasma, Inc. n=155
NCT00600886 COMPLETED
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Novartis Pharmaceuticals n=358
NCT00765323 TERMINATED
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Endo Pharmaceuticals n=169
NCT01295060 TERMINATED
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
Endo Pharmaceuticals n=12
NCT00642421 TERMINATED
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Ambrilia Biopharma, Inc. n=40
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only